Weight Loss Drug

Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide demonstrated up to...

Hims & Hers Health Inc. (NYSE:HIMS) is suddenly looking like the hottest prescription in town – up 220% in the past year and turning heads with a bold new partnership that might just reshape digital healthcare. The company announced a long-term collaboration with pharmaceutical...

Novo Nordisk A/S (NYSE:NVO) has been on a tear in the weight loss drug race, but its stock is slimming down for all the wrong reasons. Shares have plunged 44.14% over the past year, 17.4% year-to-date, and 19.27% in the last month. The Novo Nordisk stock fell to a fresh 52-week low of $72.15 — a...

An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in the battle between two health care companies seeing revenue growth and soaring stock prices as interest in weight-loss drugs grows. What Happened: A post from Musk on Christmas shared his latest take on...

Novo Nordisk A/S (NYSE:NVO) is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the release of Phase 3 trial data. While the headlines point to a new trial result that failed to meet expectations, the technical analysis reveals a deeper, more concerning picture...

On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3). Once-weekly, subcutaneous...

Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) have dominated the obesity drug market with their leading therapies, Wegovy and Zepbound, but the next generation of treatments could shift this dynamic. These new drugs, expected to hit the market by 2029, aim to surpass current efficacy...

A new study has found that people with a history of opioid abuse who took Novo Nordisk‘s (NYSE:NVO) Ozempic weight loss drug were significantly less likely to overdose, adding to growing evidence suggesting that the drug, primarily used for diabetes and weight loss, could help manage drug...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc (NASDAQ:VKTX) with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65. At the core of this bullish outlook is Viking’s obesity drug...

The rivalry between Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) has heated up as both companies vie for dominance in the booming obesity-drug market. But for investors, the real story may lie beyond just weight-loss treatments. Novo Nordisk & Eli Lilly – Expanding Beyond...

GLP-1 agonists, drugs like Novo Nordisk A/S’s (NYSE:NVO) Ozempic, Wegovy, and Eli Lilly And Co’s (NYSE:LLY) Zepbound, have revolutionized the treatment of obesity and diabetes. Now, researchers are investigating their potential to address a range of other conditions, including addiction...

Thursday, Eli Lilly and Company (NYSE:LLY) released topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg, or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. HFpEF accounts for...

Wednesday, Roche Holdings AG (OTC:RHHBY) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for type 2 diabetes and obesity. CT-996 is an investigational, once-daily oral small molecule GLP-1 receptor agonist being developed for type 2 diabetes and...

Novo Nordisk A/S (NYSE:NVO) has reportedly filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss drug, Wegovy. This move brings the total number of lawsuits by...

Novo Nordisk A/S (NYSE:NVO) has disclosed that it retains approximately 60% of the list price of its diabetes and obesity medications, Ozempic and Wegovy, in the U.S. after accounting for rebates and fees paid to intermediaries. This revelation comes amid intensifying...